All In Biotech

NDA 021929 · Astrazeneca

Symbicort

Budesonide, Formoterol Fumarate Dihydrate · Inhalation · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Dec 20, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jul 21, 2006

Approved uses

5

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

97,875

59,185 serious, 6,740 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2026.

BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: Treatment of asthma in patients 6 years of age and older. ( 1.1 ) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) 1.1 Treatment of Asthma BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is indicated for the treatment of asthma in patients 6 years of age and older. BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta2-adrenergic agonist (LABA). Important Limitations of Use: BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is NOT indicated for the relief of acute bronchospasm. 1.2 Maintenance Treatment of Chronic Obstructive Pulmonary Disease BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL 160/4.5 is also indicated to reduce exacerbations of COPD. BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL 160/4.5 is the only strength indicated for the treatment of COPD. Important Limitations of Use: BUDESONIDE AND FORMOTEROL...

Mechanism: BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL contains both budesonide and formoterol; therefore, the mechanisms of action described below for the individual components apply to BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL. These drugs represent two classes of medications (a synthetic corticosteroid and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical, physiological, and inflammatory indices of COPD and asthma. Budesonide Budesonide is an...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SYMBICORT · BUDESONIDE 0.16MG/INH; FORMOTEROL FUMARATE DIHYDRATE 0.0045MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB
  • SYMBICORT · BUDESONIDE 0.08MG/INH; FORMOTEROL FUMARATE DIHYDRATE 0.0045MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea17,904
  • asthma12,227
  • cough8,045
  • drug ineffective6,922
  • off label use5,977
  • pneumonia5,945
  • wheezing5,768
  • fatigue5,483
  • malaise4,658
  • headache4,655
  • chronic obstructive pulmonary disease4,067
  • nausea4,063

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200450
200584
2006122
2007385
20081,061
20091,445
20102,520
20113,764
20124,860
20132,977
20144,356
20155,965
20167,206
20176,586
20187,229
20197,850
20208,937
20216,807
20225,616
20235,468
20245,820
20254,948
20263,819

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Symbicort (Budesonide/Formoterol Fumarate)

2024 spending

$598M

Beneficiaries

588,018

1,913,647 claims

Per beneficiary

$1,017

$21.94 per unit

View as table
YearSpending
2020$1,979,983,682
2021$1,952,249,973
2022$1,964,824,955
2023$2,004,295,918
2024$597,805,783

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,125 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.